A new cost-effectiveness analysis, based on the Medtronic-sponsored CRYSTAL AF trial, supports implantable cardiac monitors (ICMs) as the first option for diagnosing atrial fibrillation in patients who have suffered a stroke of uncertain origin.
Researchers led by Laura Sawyer, the scientific director of London-based consulting firm Symmetron Ltd, assessed the cost-effectiveness of ICMs in...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?